World Drug Delivery and Formulation 2011

17th - 18th January 2011

Maritim ProArte Hotel Berlin, Germany

Do-Coop Technologies Ltd. Details

Do-Coop Technologies Ltd.

Company Profile:

Do-Coop Technologies Ltd., founded in 1997, is a private intellectual property company based in Israel, specializing in the manufacture and commercialization of its novel and proprietary water-based nanotechnology, Neowater®. Neowater addresses key challenges in the life science industry such as predictability, efficacy, bioavailability, solubility, toxicity and stability.

Do-Coop has 15 patent applications. Two core patents, for process and composition, have been granted in the EU, Australia and South Africa, with other territories pending.

*Do-Coop Technologies has submitted a Type IV drug master file to the FDA for Neowater and obtained ISO 9001:2000 and ISO 14001:2004 qualifications for its facility.

Key Products:

Neowater®, Do-Coop revolutionary water based nanotechnology, allows better hydration, bioavailability and efficacy of hydrophobic and hydrophilic drugs, stability of proteins and cell cultures, opens the therapeutic window  and reduces the need for surfactants and co-solvents.

With Neowater®, pharma and biotech companies can regain their investments in existing compounds, reduce time to market, enhance delivery, and maintain or increase exclusive market penetration. Neowater® provides a natural, nontoxic solution that can be widely deployed with minimal customization. Formulating compounds with Neowater® maintains or enhances the efficacy of compounds without the risks of toxicity - moving drugs more rapidly through the development cycle.   

Website:
www.docoop.com